Abstract
Patients with chronic inflammatory diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus, psoriasis and Crohns disease have an increased atherosclerotic risk which cannot be explained by traditional cardiovascular risk factors alone. Inflammatory pathways are implicated in this increased vascular risk. The involvement of cytokine – related signaling pathways in inflammatory diseases has prompted the development of many therapeutic strategies aimed at their modulation to limit disease severity and progression. Whether modulation of these pathways would similarly alter the inflammatory processes related to accelerated atherosclerosis remains unknown. In this review we will focus on the role of pro-inflammatory cytokines and their inhibitors in RA, and whether they may be causal in the accelerated atherosclerosis seen in these patients.
Keywords: Rheumatoid arthritis, cytokine, inflammation, atherosclerosis, anti-microbial and anti-fungicidal properties, L tryptophane, in-dole glucosinolates, alkenyl glucosinolates, bio-fumigants, 2, –, oxazolidimethione, N, hydroxy-amino acid, aldoxime, hydroxy acid, de-sulpho glucosinolate, Moringaceae
Current Pharmaceutical Design
Title: Cytokines as Therapeutic Targets to Reduce Cardiovascular Risk in Chronic Inflammation
Volume: 17 Issue: 1
Author(s): Ashley M. Miller and Iain B. McInnes
Affiliation:
Keywords: Rheumatoid arthritis, cytokine, inflammation, atherosclerosis, anti-microbial and anti-fungicidal properties, L tryptophane, in-dole glucosinolates, alkenyl glucosinolates, bio-fumigants, 2, –, oxazolidimethione, N, hydroxy-amino acid, aldoxime, hydroxy acid, de-sulpho glucosinolate, Moringaceae
Abstract: Patients with chronic inflammatory diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus, psoriasis and Crohns disease have an increased atherosclerotic risk which cannot be explained by traditional cardiovascular risk factors alone. Inflammatory pathways are implicated in this increased vascular risk. The involvement of cytokine – related signaling pathways in inflammatory diseases has prompted the development of many therapeutic strategies aimed at their modulation to limit disease severity and progression. Whether modulation of these pathways would similarly alter the inflammatory processes related to accelerated atherosclerosis remains unknown. In this review we will focus on the role of pro-inflammatory cytokines and their inhibitors in RA, and whether they may be causal in the accelerated atherosclerosis seen in these patients.
Export Options
About this article
Cite this article as:
M. Miller Ashley and B. McInnes Iain, Cytokines as Therapeutic Targets to Reduce Cardiovascular Risk in Chronic Inflammation, Current Pharmaceutical Design 2011; 17 (1) . https://dx.doi.org/10.2174/138161211795049796
DOI https://dx.doi.org/10.2174/138161211795049796 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Detection of Ventricular Arrhythmias using HRV Analysis and Quadratic Features
Recent Advances in Electrical & Electronic Engineering Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Agonists on Glycemic Control, Lipid Profile and Cardiovascular Risk
Current Molecular Pharmacology Osteoporotic Fracture Healing: Potential Use of Medicinal Plants from the Tropics
Current Drug Targets Understanding Heterogeneity in Supplementation Effects of Selenium in Men: A Study of Stratification Variables and Human Genetics in a Prospective Sample from New Zealand
Current Pharmacogenomics and Personalized Medicine Effects of Different Types of Physical Exercise on the Perceived Quality of Life in Active Elderly
CNS & Neurological Disorders - Drug Targets Clinical Application of Ghrelin
Current Pharmaceutical Design Asymptomatic Lone Atrial Fibrillation - How can we Detect the Arrhythmia?
Current Pharmaceutical Design The Role of Anaphylatoxins C3a and C5a in Regulating Innate and Adaptive Immune Responses
Inflammation & Allergy - Drug Targets (Discontinued) A Critical Review of Bioactive Food Components, and of their Functional Mechanisms, Biological Effects and Health Outcomes
Current Pharmaceutical Design Prevention of Sudden Cardiac Death in Hemodialysis Patients
Cardiovascular & Hematological Disorders-Drug Targets Genetic Signatures in the Treatment of Stroke
Current Pharmaceutical Design Biological Abilities of Rice Bran-Derived Antioxidant Phytochemicals for Medical Therapy
Current Topics in Medicinal Chemistry Lysophosphatidic Acid and Ischemic Stroke
Vascular Disease Prevention (Discontinued) Polymeric Nanotubes and Nanorods for Biomedical Applications
Current Nanoscience Statins in Stroke Prevention: Present and Future
Current Pharmaceutical Design Mitochondrial Aldehyde Dehydrogenase, A Potential Drug Target for Protection of Heart and Brain from Ischemia/Reperfusion Injury
Current Drug Targets The Interaction of Depression and Diabetes: A Review
Current Diabetes Reviews Microcirculatory Endothelial Dysfunction During Endotoxemia - Insights into Pathophysiology, Pathologic Mechanisms and Clinical Relevance
Current Vascular Pharmacology Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology